医药高增长轮动策略:年化收益率(5.6%)

本策略精选医药生物行业中,净利润和营收均高速增长、毛利率和净利率优秀、市盈率适中,且流通市值较小的优质股票。策略通过严格的财务指标筛选,并结合小市值偏好,力求捕捉医药行业中具备高成长潜力的投资标的,并进行短期轮动持有,以期获得超额收益。

概要

核心指标

  • 累计收益率: 8.63%
  • 年化收益率: 5.6%
  • 基准收益率: 19.74%
  • 阿尔法: -0.02
  • 夏普比率: 0.24
  • 最大回撤: 13.17%

源码

查看AI策略代码

绩效

持仓详情

当日收盘价
当日市值
浮动收益/浮动收益率
2025-08-01 甘李药业(603087.SH) 48.368603968939 1830 62 60.99 111611.7 23097.15/26.094%
2025-08-01 昊帆生物(301393.SZ) 48.364578054629 1909 62 59.05 112726.45 20398.47/22.093%
2025-08-01 大博医疗(002901.SZ) 33.655879985364 2433 67 44.68 108706.44 26821.68/32.755%
2025-08-01 兴齐眼药(300573.SZ) 55.206555555556 1700 12 61.75 104975 11123.86/11.853%
2025-08-01 宣泰医药(688247.SH) 10.709931934519 8533 182 12.41 105894.53 14506.68/15.874%
2025-08-01 特宝生物(688278.SH) 61.435341940248 1239 322 90.73 112414.47 36296.08/47.684%
2025-07-31 甘李药业(603087.SH) 48.368603968939 1830 61 57.9 105957 17442.45/19.706%
2025-07-31 昊帆生物(301393.SZ) 48.364578054629 1909 61 61.69 117766.21 25438.23/27.552%
2025-07-31 大博医疗(002901.SZ) 33.655879985364 2433 66 44.26 107684.58 25799.82/31.507%
2025-07-31 兴齐眼药(300573.SZ) 55.206555555556 1700 11 64.53 109701 15849.86/16.888%

交易详情

2025-07-31 宣泰医药(688247.SH) -200 12.6 -2520 ¥7.52 378.01
2025-07-31 兴齐眼药(300573.SZ) -100 64.09 -6409 ¥11.41 888.34
2025-07-24 宣泰医药(688247.SH) -500 11.8 -5900 ¥10.9 545.03
2025-07-24 大博医疗(002901.SZ) -100 43.18 -4318 ¥9.32 952.41
2025-07-17 兴齐眼药(300573.SZ) 1800 55.19 99342 ¥29.8 0
2025-07-17 大博医疗(002901.SZ) -200 41.25 -8250 ¥13.25 1518.82
2025-07-10 宣泰医药(688247.SH) -400 10.67 -4268 ¥9.27 -15.97
2025-06-27 宣泰医药(688247.SH) 38 10.08 -0.76 ¥0 0
2025-06-26 昊帆生物(301393.SZ) 100 51.18 5118 ¥5 0
2025-06-19 大博医疗(002901.SZ) 100 35.5 3550 ¥5 0